Full Press Release Details
Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn.,
December 14, 2023 (GlobeNewswire) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the
"Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from
neurological disorders, today announces its operating results for the fiscal fourth quarter and full fiscal year ended September 30, 2023.
Fiscal Fourth Quarter
2023 and Recent Business Updates
Financial Highlights:
Spinal Cord Stimulation
Drug Delivery Program:
Dave Rosa, CEO of NeuroOne, commented,
"During and subsequent to our fiscal fourth quarter, the Company continued to execute at a high level on our strategic plan.
We were proud to announce the FDA clearance of our OneRF Ablation System, the Company's first device that has an indication
for both recording electrical activity as well as ablation of nervous tissue and the first device with an FDA clearance. We believe
this device has the capability to create a paradigm shift in neurosurgical procedures. We expect to commercially launch this product
either directly or with a strategic partner in the first half of 2024. This represents the third FDA clearance in the
Company's history and a monumental achievement. In addition, Zimmer Biomet continues to expand the commercial launch of our
Evo sEEG electrode as centers receive approval from their respective product committees to trial the technology. We also continue to
be bullish on the opportunity to deliver drugs or gene therapies and record the impact of these therapies using our sEEG electrode.
We have already held discussions with a Company that has strong interest in using our electrode in their clinical trial to evaluate
the performance of their therapy. The Company has made great strides in all areas, and I look forward to continuing to lead the
Company as we execute our strategic plan."
Upcoming Targeted Milestones
OneRF Ablation System:
Drug Delivery Program:
Full Fiscal Year 2023 Financial Results
Product revenue was $742,000 in
the fourth quarter of fiscal 2023 and $1,952,000 for the full fiscal year, compared to product revenue of $69,000 in the fourth quarter
and $171,000 for the full year of fiscal 2022. The Company had no collaboration revenue in the fourth quarter of fiscal 2023 and $1,455,000
for the full year of fiscal 2023, compared to collaboration revenue of $1,942,000 in the fourth quarter and $1,949,000 for the full year
of fiscal 2022. Collaboration revenue was derived from the Zimmer Development Agreement and represents the portion of the exclusivity
and milestone fee payments eligible for revenue recognition during the respective periods.
Total operating expenses
in the fourth quarter of fiscal 2023 were $3.4 million, compared with $3.3 million in the same period of the prior year.
R&D expense in the fourth quarter of fiscal 2023 was $1.8 million compared with $1.4 million in the same period
of fiscal 2022. SG&A expense in the fourth quarter of fiscal 2023 was $1.6 million compared with $1.9 million in
the same period of the prior year.
Total operating expenses
for the full fiscal year 2023 were $13.9 million, compared with $11.9 million in the prior fiscal year. R&D expense
for the full fiscal year 2023 was $6.9 million compared with $4.9 million in fiscal 2022. SG&A expense for the
full fiscal year 2023 was $6.9 million compared with $7.0 million in the same period of the prior year.
was $3.1 million for the fourth quarter of fiscal 2023, compared to a net loss of $1.4 million in the same
period of the prior year. Net loss was $11.9 million for the full year fiscal 2023, compared to a net loss
of $10.0 million in fiscal 2022.
On July 27, 2023, the
Company completed an underwritten public offering of its common stock from which the Company received $5.2 million in net proceeds. In
addition, the Company sold common stock under the ATM program at an average price of $1.77 per share, from which the Company received
net proceeds of $2.5 million.
30, 2023, the Company had cash, cash equivalents, and short-term investments of $5.3 million, compared to $11.1 million as
of September 30, 2022. The Company had working capital of $5.5 million as of September 30, 2023, compared to working capital of $9.1
million as of September 30, 2022.
The Company had no debt
outstanding as of September 30, 2023.
NeuroOne Medical Technologies Corporation is a
developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation
and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due
to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company
may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial
intelligence. For more information, visit nmtc1.com.
Forward Looking Statements
may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this
press release may be a forward-looking statement that reflects NeuroOne's current views about future events and are
subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from the information expressed or implied by these forward-looking
statements. In some cases, you can identify forward-looking statements by the words or phrases "may,"
"might," "will," "could," "would," "should," "expect,"
"intend," "plan," "objective," "anticipate," "believe,"
"estimate," "predict," "project," "potential," "target,"
"seek," "contemplate," "continue, "focused on," "committed to" and
"ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the
future. Forward-looking statements may include statements regarding the development of the Company's electrode
technology program, applications for, or receipt of, regulatory clearance, the timing and extent of product launch and
commercialization of our technology, receipt of revenues from sale of the sEEG electrodes, timing and success of any clinical and
pre-clinical testing, the timing and extent of product launch and commercialization of our OneRF Ablation System, the potential
capabilities of our OneRF Ablation System, SCS and drug delivery programs, business strategy, market size, potential growth opportunities,
future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a
reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and
factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be
materially different from what we expect due to factors largely outside our control, including risks that the partnership with
Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain
disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on
results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company's capital
requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or
retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology;
risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately
estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the
results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and
assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the date of this press release and NeuroOne undertakes no
obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the
Caution: Federal law
restricts this device to sale by or on the order of a physician.
NeuroOne Medical Technologies Corporation
| As of September 30, | ||||||||
| 2023 | 2022 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,322,493 | $ | 8,160,329 | ||||
| Short-term investments | - | 2,981,010 | ||||||
| Accounts receivable | - | 33,237 | ||||||
| Inventory | 1,726,686 | 704,538 | ||||||
| Prepaid expenses | 263,746 | 296,649 | ||||||
| Total current assets | 7,312,925 | 12,175,763 | ||||||
| Intangible assets, net | 89,577 | 111,892 | ||||||
| Right-of-use asset | 169,059 | 181,355 | ||||||
| Property and equipment, net | 525,753 | 353,599 | ||||||
| Total assets | $ | 8,097,314 | $ | 12,822,609 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 685,104 | $ | 927,662 | ||||
| Accrued expenses and other liabilities | 1,107,522 | 715,839 | ||||||
| Deferred revenue | - | 1,455,188 | ||||||
| Total current liabilities | 1,792,626 | 3,098,689 | ||||||
| Operating lease liability, long term | 55,284 | 119,556 | ||||||
| Total liabilities | 1,847,910 | 3,218,245 | ||||||
| Commitments and contingencies (Note 4) | ||||||||
| Stockholders' equity: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized as of September 30, 2023 and 2022; no shares issued or outstanding as of September 30, 2023 and 2022. | - | - | ||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized as of September 30, 2023 and 2022; 23,928,945 and 16,216,540 shares issued and outstanding as of September 30, 2023 and 2022, respectively. | 23,929 | 16,217 | ||||||
| Additional paid-in capital | 68,911,778 | 60,414,959 | ||||||
| Accumulated deficit | (62,686,303 | ) | (50,826,812 | ) | ||||
| Total stockholders' equity | 6,249,404 | 9,604,364 | ||||||
| Total liabilities and stockholders' equity | $ | 8,097,314 | $ | 12,822,609 |
NeuroOne Medical Technologies Corporation
Statements of Operations
| Years ended September 30, | ||||||||
| 2023 | 2022 | |||||||
| Product revenue | $ | 1,952,441 | $ | 171,169 | ||||
| Cost of product revenue | 1,495,924 | 241,963 | ||||||
| Product gross profit (loss) | 456,517 | (70,794 | ) | |||||
| Collaboration revenue | 1,455,188 | 1,948,872 | ||||||
| Operating expenses: | ||||||||
| Selling, general and administrative | 6,926,269 | 6,979,416 | ||||||
| Research and development | 6,940,686 | 4,929,427 | ||||||
| Total operating expenses | 13,866,955 | 11,908,843 | ||||||
| Loss from operations | (11,955,250 | ) | (10,030,765 | ) | ||||
| Other income, net | 95,759 | 31,152 | ||||||
| Net loss | $ | (11,859,491 | ) | $ | (9,999,613 | ) | ||
| Net loss per share: | ||||||||
| Basic and diluted | $ | (0.65 | ) | $ | (0.63 | ) | ||
| Number of shares used in per share calculations: | ||||||||
| Basic and diluted | 18,121,108 | 15,998,567 |